Regen BioPharma Inc (RGBP)

[Watsonturtle]

Thanks for the feedback.

I am not an expert, but I have a light understanding about the current testing, what it's about and what it's not about.

What it's not about: The patent for screening compounds (molecules) that modulate NR2F6 is very interesting. That testing has been done (which is the more difficult testing step). Target compounds have been identified. Patents have been applied for those compounds.

What it's about: Not certain this is correct, but the current testing is about understanding the details of how those compounds modulate the NR2F6 checkpoint (i.e., to aid in perfecting, to aid in understanding potential safety issues, to aid in preparing phase 1 clinical applications). In other words, it's not about finding a target (the most difficult step), it's about perfecting the targets and getting data and information for the clinicals.

I do not know what negative data would look like in the current testing... and I am not certain this is about good data or bad data. Any data that guides or sheds light on how the compounds modulate the check would seem to have value.

If true, IMHO, sure seems like a very favorable risk/reward at this point.

Here's a question: what's the value of the company after this testing is complete, and we head into phase 1 clinicals?